IBDEI0NJ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11584,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,11584,1,2,0)
 ;;=2^LYMPHOMA,MARGINAL ZONE
 ;;^UTILITY(U,$J,358.3,11584,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,11585,0)
 ;;=200.50^^79^761^33
 ;;^UTILITY(U,$J,358.3,11585,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11585,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,11585,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS
 ;;^UTILITY(U,$J,358.3,11585,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,11586,0)
 ;;=202.90^^79^761^32
 ;;^UTILITY(U,$J,358.3,11586,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11586,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,11586,1,2,0)
 ;;=2^LYMPHOMA,OTHER SITE
 ;;^UTILITY(U,$J,358.3,11586,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,11587,0)
 ;;=200.10^^79^761^34
 ;;^UTILITY(U,$J,358.3,11587,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11587,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,11587,1,2,0)
 ;;=2^LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,11587,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11588,0)
 ;;=172.9^^79^761^35
 ;;^UTILITY(U,$J,358.3,11588,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11588,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,11588,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,11588,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,11589,0)
 ;;=199.0^^79^761^37
 ;;^UTILITY(U,$J,358.3,11589,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11589,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,11589,1,2,0)
 ;;=2^METASTATIC CA OF UNKN PRIMARY
 ;;^UTILITY(U,$J,358.3,11589,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,11590,0)
 ;;=203.00^^79^761^38
 ;;^UTILITY(U,$J,358.3,11590,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11590,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,11590,1,2,0)
 ;;=2^MULTIPLE MYELOMA
 ;;^UTILITY(U,$J,358.3,11590,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,11591,0)
 ;;=238.75^^79^761^39
 ;;^UTILITY(U,$J,358.3,11591,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11591,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,11591,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,11591,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,11592,0)
 ;;=157.9^^79^761^41
 ;;^UTILITY(U,$J,358.3,11592,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11592,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,11592,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,11592,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,11593,0)
 ;;=187.9^^79^761^42
 ;;^UTILITY(U,$J,358.3,11593,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11593,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,11593,1,2,0)
 ;;=2^PENILE CANCER
 ;;^UTILITY(U,$J,358.3,11593,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,11594,0)
 ;;=163.9^^79^761^44
 ;;^UTILITY(U,$J,358.3,11594,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11594,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,11594,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,11594,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,11595,0)
 ;;=185.^^79^761^45
 ;;^UTILITY(U,$J,358.3,11595,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11595,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,11595,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,11595,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,11596,0)
 ;;=287.9^^79^761^46
 ;;^UTILITY(U,$J,358.3,11596,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11596,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,11596,1,2,0)
 ;;=2^PURPURA/OTH HEMORRHAGIC COND
 ;;^UTILITY(U,$J,358.3,11596,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,11597,0)
 ;;=154.3^^79^761^47
 ;;^UTILITY(U,$J,358.3,11597,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11597,1,1,0)
 ;;=1^154.3
 ;;^UTILITY(U,$J,358.3,11597,1,2,0)
 ;;=2^RECTAL CANCER
 ;;^UTILITY(U,$J,358.3,11597,2)
 ;;=^267092
 ;;^UTILITY(U,$J,358.3,11598,0)
 ;;=189.9^^79^761^62
